Professor Martin Landray
- Modelling adverse event processing in clinical trials Research Group
- Funded DPhil project: An investigation into the utility of smartphone-based citizen science projects for understanding brain health Research Group
- HPS3 / TIMI 55 - REVEAL : Randomised EValuation of the Effects of Anacetrapib through Lipid-modification Research Group
- SHARP: Study of Heart and Renal Protection Research Group
- Trials Methodology Research Group
- Research Regulation Research Group
MB ChB, PhD, FRCP, FHEA, FASN, FBPhS, FESC
Professor of Medicine and Epidemiology; Deputy Director, Big Data Institute
- MRC PHRU Programme Leader - Clinical Trial Service & Epidemiological Studies Unit
- Honorary Consultant Physician - Cardiology, Cardiac and Thoracic Surgery Directorate, Oxford University Hospitals NHS Foundation Trust
Martin Landray is Professor of Medicine and Epidemiology within the Nuffield Department of Population Health and Deputy Director of the Big Data Institute within the Li Ka Shing Centre for Health Information and Discovery.
His work seeks to further understanding of the determinants of common life-threatening and disabling diseases through the design, conduct and analysis of efficient, large-scale epidemiological studies (including clinical trials) and the widespread dissemination of both the results and the scientific methods used to generate them. He leads international trials that have enrolled over 65,000 individuals with cardiovascular or kidney disease from 18 countries across 4 continents, and the results of completed studies have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients.
He leads the Health Informatics Hub for UK Biobank, a prospective cohort study of 500,000 middle-aged men and women, and the Big Data & Clinical Informatics theme for the Oxford Academic Health Science Centre.
He is heavily involved in efforts to streamline clinical trials, working with national and international organizations (including FDA, EMA, MHRA, MRC) to facilitate high quality research is efficient in providing robust information for healthcare decision-making. He is a member of the Steering Committee of the FDA Clinical Trial Transformation Initiative, leading the Monitoring, Quality by Design and Mobile Clinical Trials projects. He has served as a member of the NIHR Commissioning Board and the External Reference Panel for the Ministerial (Biopharmaceutical) Industry Strategy Group Research through Health Data Programme, and is a member of the NHS Digital Research Advisory Group.
Martin Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Cardiology, Cardiac and Thoracic Surgery Directorate at Oxford University Hospitals NHS Trust. He is a Fellow of the Royal College of Physicians of London, the Higher Education Academy, the American Society of Nephrology, the British Pharmacological Society, and the European Society of Cardiology.
Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)—A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
Landray MJ. and REVEAL Collaborative Group None., (2017), American Heart Journal, 187, 182 - 190
Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.
Mafham MM. et al, (2017), Nephrol Dial Transplant
Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study
McConnell MV. et al, (2016), JAMA Cardiology
Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).
Staplin N. et al, (2016), American Journal of Kidney Diseases, 68, 371 - 380
Enhancing clinical evidence by proactively building quality into clinical trials.
Meeker-O'Connell A. et al, (2016), Clinical trials (London, England), 13, 439 - 444
IN the News
Lectures, webcasts and interviews
Big Trials, Big Data, Big Potential: population health research in the 21st century
Inaugural Lecture, University of Oxford, November 2015
New Technologies for Healthcare Research
Oxford Martin School, University of Oxford, January 2016
Big Data for Efficient Clinical Trials
National Academy of Medicine, Washington DC, October 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2015
Quality by Design for Clinical Trials
Clinical Trial Transformation Initiative, Bethesda, April 2015
Big Data in Biomedicine
Interview, Stanford Medicine, May 2014
Big Data and Drug Discovery
University of Oxford Alumni, October 2013